A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, China
Contact: Study coordinator (Yong yi Zeng) · lamp197311@126.com · 0591-88112829

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Philadelphia, United States

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Wuhan, China